Galectin Therapeutics Inc

Insider buying by Galectin Therapeutics’ CMO signals confidence in belapectin and a potential upside, sparking investor interest and a modest weekly gain.

CEO Lewis Joel sells 56k Galectin Therapeutics shares—what the move means for insider confidence, liquidity, and the company’s future.